Blair William & Co. IL trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 804,257 shares of the biopharmaceutical company’s stock after selling 128,459 shares during the period. Blair William & Co. IL owned about 0.06% of Gilead Sciences worth $60,126,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in GILD. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $859,602,000. Capital Research Global Investors increased its stake in Gilead Sciences by 10.9% in the fourth quarter. Capital Research Global Investors now owns 85,132,885 shares of the biopharmaceutical company’s stock valued at $5,531,935,000 after purchasing an additional 8,343,863 shares during the last quarter. Valueworks LLC increased its stake in Gilead Sciences by 7,777.5% in the fourth quarter. Valueworks LLC now owns 4,919,000 shares of the biopharmaceutical company’s stock valued at $6,146,000 after purchasing an additional 4,856,556 shares during the last quarter. AQR Capital Management LLC increased its stake in Gilead Sciences by 59.2% in the fourth quarter. AQR Capital Management LLC now owns 7,208,716 shares of the biopharmaceutical company’s stock valued at $464,529,000 after purchasing an additional 2,682,046 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Gilead Sciences by 15.1% in the fourth quarter. Renaissance Technologies LLC now owns 16,962,944 shares of the biopharmaceutical company’s stock valued at $1,102,252,000 after purchasing an additional 2,228,686 shares during the last quarter. Hedge funds and other institutional investors own 77.34% of the company’s stock.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 13,210 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the completion of the sale, the executive vice president now owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $83.00, for a total value of $200,279.00. Following the completion of the transaction, the director now owns 57,273 shares of the company’s stock, valued at approximately $4,753,659. The disclosure for this sale can be found here. In the last three months, insiders sold 60,585 shares of company stock valued at $4,671,283. 0.13% of the stock is owned by corporate insiders.
Several brokerages have commented on GILD. Cowen reiterated a “buy” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Monday, April 13th. Barclays began coverage on shares of Gilead Sciences in a research note on Thursday, February 27th. They issued an “underweight” rating and a $62.00 price target on the stock. Credit Suisse Group reiterated a “sell” rating and issued a $60.00 price target on shares of Gilead Sciences in a research note on Friday, April 17th. ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. Finally, BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday. Seven research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $78.15.
Gilead Sciences stock traded down $0.16 during midday trading on Friday, reaching $73.34. The company’s stock had a trading volume of 6,157,451 shares, compared to its average volume of 19,139,120. Gilead Sciences, Inc. has a fifty-two week low of $60.89 and a fifty-two week high of $85.97. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. The stock’s 50 day simple moving average is $77.78 and its 200 day simple moving average is $70.16. The firm has a market capitalization of $92.20 billion, a PE ratio of 18.85, a P/E/G ratio of 3.14 and a beta of 0.72.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The company had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter last year, the company earned $1.67 earnings per share. Gilead Sciences’s quarterly revenue was up 5.1% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 6.34 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Friday, June 12th will be issued a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date is Thursday, June 11th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.30%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Is a Roth IRA right for you?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.